• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

勘误：无进展生存期和疾病进展时间作为局限期小细胞肺癌放化疗试验中总生存期潜在替代终点的系统评价和荟萃分析。

Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis.

作者信息

Yang Yin, Wang Jianyang, Wang Wenqing, Zhang Tao, Zhao Jingjing, Wang Yu, Li Yexiong, Wang Luhua, Bi Nan

机构信息

Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.

出版信息

Front Oncol. 2022 Aug 24;12:1007862. doi: 10.3389/fonc.2022.1007862. eCollection 2022.

DOI:10.3389/fonc.2022.1007862
PMID:36091135
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9462661/
Abstract

[This corrects the article DOI: 10.3389/fonc.2022.810580.].

摘要

[本文更正了文章DOI：10.3389/fonc.2022.810580。]

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b130/9462661/f58fab565345/fonc-12-1007862-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b130/9462661/a2c11a1d95ff/fonc-12-1007862-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b130/9462661/f58fab565345/fonc-12-1007862-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b130/9462661/a2c11a1d95ff/fonc-12-1007862-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b130/9462661/f58fab565345/fonc-12-1007862-g003.jpg

相似文献

1
Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis.勘误：无进展生存期和疾病进展时间作为局限期小细胞肺癌放化疗试验中总生存期潜在替代终点的系统评价和荟萃分析。
Front Oncol. 2022 Aug 24;12:1007862. doi: 10.3389/fonc.2022.1007862. eCollection 2022.
2
Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.无进展生存期和至疾病进展时间作为局限期小细胞肺癌放化疗试验中总生存期潜在替代终点的系统评价和荟萃分析
Front Oncol. 2022 Jan 28;12:810580. doi: 10.3389/fonc.2022.810580. eCollection 2022.
3
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.可手术和局部晚期肺癌化疗和放疗试验中总生存的替代终点：对个体患者数据荟萃分析的重新分析。
Lancet Oncol. 2013 Jun;14(7):619-26. doi: 10.1016/S1470-2045(13)70158-X. Epub 2013 May 14.
4
Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.Meta 分析评估癌症随机试验中总生存的替代终点：批判性评价。
Crit Rev Oncol Hematol. 2018 Mar;123:21-41. doi: 10.1016/j.critrevonc.2017.11.014. Epub 2017 Nov 23.
5
Surrogate endpoints for overall survival in lung cancer trials: a review.肺癌试验中总生存期的替代终点：综述
Expert Rev Anticancer Ther. 2017 May;17(5):447-454. doi: 10.1080/14737140.2017.1316196. Epub 2017 Apr 12.
6
Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer.在前列腺癌临床试验中寻找总生存的潜在替代终点。
Cancer Rep (Hoboken). 2021 Jun;4(3):e1334. doi: 10.1002/cnr2.1334. Epub 2021 Jan 17.
7
Evaluation of potential surrogate endpoints for prediction of overall survival in patients with castration-resistant prostate cancer: trial-level meta-analysis.评估潜在替代终点预测去势抵抗性前列腺癌患者总生存期的价值：试验水平的荟萃分析。
Eur J Clin Pharmacol. 2019 Nov;75(11):1521-1532. doi: 10.1007/s00228-019-02736-8. Epub 2019 Aug 28.
8
Surrogate endpoints for overall survival in combined chemotherapy and radiotherapy trials in nasopharyngeal carcinoma: Meta-analysis of randomised controlled trials.鼻咽癌放化疗联合试验中总生存期的替代终点：随机对照试验的荟萃分析
Radiother Oncol. 2015 Aug;116(2):157-66. doi: 10.1016/j.radonc.2015.07.030. Epub 2015 Aug 1.
9
Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.广泛期小细胞肺癌中肿瘤缓解和无进展生存期作为总生存期替代终点的潜力：基于西北肿瘤协作组试验的结果。
Cancer. 2011 Mar 15;117(6):1262-71. doi: 10.1002/cncr.25526. Epub 2010 Oct 19.
10
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?统计考虑和临床肺癌研究的终点：无进展生存期 (PFS) 是否可以替代总生存期 (OS) 作为晚期非小细胞肺癌临床试验的有效终点？
Transl Lung Cancer Res. 2012 Mar;1(1):26-35. doi: 10.3978/j.issn.2218-6751.2011.12.08.

引用本文的文献

1
A simplified scoring system for predicting treatment response in limited-stage small-cell lung cancer (EAST score).一种用于预测局限期小细胞肺癌治疗反应的简化评分系统（EAST评分）。
Future Oncol. 2025 Feb;21(4):473-481. doi: 10.1080/14796694.2024.2444858. Epub 2024 Dec 29.